.png)
mRNA Cancer Vaccines and Therapeutics Market by Type and Application - Global Industry Analysis & Forecast to 2027
Published On : May 2022 Pages : 150 Category: Biotechnology Report Code : HC0511104
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
mRNA Cancer Vaccines and Therapeutics Market by Type (Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas) Application (Infectious Disease, Cancer, Other) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The mRNA Cancer Vaccines and Therapeutics Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. mRNA Cancer Vaccines and Therapeutics is a versatile tool for the development of new innovative therapeutics. In the field of vaccine development, mRNA is an interest as it maintains the key characteristics of pDNA, but with a superior safety profile. mRNA Cancer Vaccines and Therapeutics represents the minimal vector enabling transient protein expression and does not harbor the risk of insertional mutagenesis or permanent genomic alteration.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
-
- Moderna Therapeutics
- CureVac
- Translate Bio
- BioNTech
- Sangamo Therapeutics
- Argos Therapeutics
- In-Cell-Art
- eTheRNA
- Ethris
- Tiba Biotechnology
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· mRNA Cancer Vaccines and Therapeutics Market, By Type, Estimates and Forecast, 2017-2027 ($Million)
o Adeno Carcinomas
o Mucinous Carcinomas
o Adenosquamous Carcinomas
· mRNA Cancer Vaccines and Therapeutics Market, By Application, Estimates and Forecast, 2017-2027 ($Million)
o Infectious Disease
o Cancer
o Other
· mRNA Cancer Vaccines and Therapeutics Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Moderna Therapeutics
o CureVac
o Translate Bio
o BioNTech
o Sangamo Therapeutics
o Argos Therapeutics
o In-Cell-Art
o eTheRNA
o Ethris
o Tiba Biotechnology
· mRNA Cancer Vaccines and Therapeutics Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Submarine Cables Market, By Country
o U.S. Submarine Cables Market
o Canada Submarine Cables Market
o Mexico Submarine Cables Market
o Europe
§ Europe Submarine Cables Market, By Country
o Germany Submarine Cables Market
o UK Submarine Cables Market
o France Submarine Cables Market
o Russia Submarine Cables Market
o Italy Submarine Cables Market
o Rest of Europe Submarine Cables Market
o Asia-Pacific
§ Asia-Pacific Submarine Cables Market, By Country
o China Submarine Cables Market
o Japan Submarine Cables Market
o South Korea Submarine Cables Market
o India Submarine Cables Market
o Southeast Asia Submarine Cables Market
o Rest of Asia-Pacific Submarine Cables Market
o South America
§ South America Submarine Cables Market
o Brazil Submarine Cables Market
o Argentina Submarine Cables Market
o Columbia Submarine Cables Market
o Rest of South America Submarine Cables Market
o Middle East and Africa
§ Middle East and Africa Submarine Cables Market
o Saudi Arabia Submarine Cables Market
o UAE Submarine Cables Market
o Egypt Submarine Cables Market
o Nigeria Submarine Cables Market
o South Africa Submarine Cables Market
o Rest of MEA Submarine Cables Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. MRNA Cancer Vaccines And Therapeutics Market, By Type
5.1. Introduction
5.2. Global MRNA Cancer Vaccines And Therapeutics Revenue and Market Share by Type (2017-2021)
5.2.1. Global MRNA Cancer Vaccines And Therapeutics Revenue and Revenue Share by Type (2017-2021)
5.3. Adeno Carcinomas
5.3.1. Global Adeno Carcinomas Revenue and Growth Rate (2017-2021)
5.4. Mucinous Carcinomas
5.4.1. Global Mucinous Carcinomas Revenue and Growth Rate (2017-2021)
5.5. Adenosquamous Carcinomas
5.5.1. Global Adenosquamous Carcinomas Revenue and Growth Rate (2017-2021)
6. MRNA Cancer Vaccines And Therapeutics Market, By Applications
6.1. Introduction
6.2. Global MRNA Cancer Vaccines And Therapeutics Revenue and Market Share by Applications (2017-2021)
6.2.1. Global MRNA Cancer Vaccines And Therapeutics Revenue and Revenue Share by Applications (2017-2021)
6.3. Infectious Disease
6.3.1. Global Infectious Disease Revenue and Growth Rate (2017-2021)
6.4. Cancer
6.4.1. Global Cancer Revenue and Growth Rate (2017-2021)
6.5. Other
6.5.1. Global Other Revenue and Growth Rate (2017-2021)
7. MRNA Cancer Vaccines And Therapeutics Market, By Region
7.1. Introduction
7.2. Global MRNA Cancer Vaccines And Therapeutics Revenue and Market Share by Regions
7.2.1. Global MRNA Cancer Vaccines And Therapeutics Revenue by Regions (2017-2021)
7.3. North America MRNA Cancer Vaccines And Therapeutics by Countries
7.3.1. North America MRNA Cancer Vaccines And Therapeutics Revenue and Growth Rate (2017-2021)
7.3.2. North America MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe MRNA Cancer Vaccines And Therapeutics by Countries
7.4.1. Europe MRNA Cancer Vaccines And Therapeutics Revenue and Growth Rate (2017-2021)
7.4.2. Europe MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific MRNA Cancer Vaccines And Therapeutics by Countries
7.5.1. Asia-Pacific MRNA Cancer Vaccines And Therapeutics Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America MRNA Cancer Vaccines And Therapeutics by Countries
7.6.1. South America MRNA Cancer Vaccines And Therapeutics Revenue and Growth Rate (2017-2021)
7.6.2. South America MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa MRNA Cancer Vaccines And Therapeutics by Countries
7.7.1. Middle East and Africa MRNA Cancer Vaccines And Therapeutics Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Moderna Therapeutics
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. CureVac
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Translate Bio
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. BioNTech
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Sangamo Therapeutics
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Argos Therapeutics
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. In-Cell-Art
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. eTheRNA
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Ethris
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. Tiba Biotechnology
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.1. Global MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. MRNA Cancer Vaccines And Therapeutics Market Forecast by Regions (2022-2027)
9.2.1. North America MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.1.1. United States MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.1.2. Canada MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.1.3. Mexico MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.2. Europe MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.2.1. Germany MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.2.2. France MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.2.3. UK MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.2.4. Russia MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.2.5. Italy MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.2.6. Rest of Europe MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.3. Asia-Pacific MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.3.1. China MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.3.2. Japan MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.3.3. Korea MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.3.4. India MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.3.5. Southeast Asia MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.4. South America MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.4.1. Brazil MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.4.2. Argentina MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.4.3. Columbia MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.4.4. Rest of South America MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.5. Middle East and Africa MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.5.3. Egypt MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.5.4. Nigeria MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.5.5. South Africa MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.5.6. Turkey MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa MRNA Cancer Vaccines And Therapeutics Market Forecast (2022-2027)
9.3. MRNA Cancer Vaccines And Therapeutics Market Forecast by Type (2022-2027)
9.3.1. MRNA Cancer Vaccines And Therapeutics Forecast by Type (2022-2027)
9.3.2. MRNA Cancer Vaccines And Therapeutics Market Share Forecast by Type (2022-2027)
9.4. MRNA Cancer Vaccines And Therapeutics Market Forecast by Applications (2022-2027)
9.4.1. MRNA Cancer Vaccines And Therapeutics Forecast by Applications (2022-2027)
9.4.2. MRNA Cancer Vaccines And Therapeutics Market Share Forecast by Applications (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure France MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure China MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure India MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) and Growth Rate (2017-2027)
Table Global MRNA Cancer Vaccines And Therapeutics Revenue and Revenue Share by Type (2017-2019)
Figure Global Adeno Carcinomas Revenue and Growth Rate (2017-2019)
Figure Global Mucinous Carcinomas Revenue and Growth Rate (2017-2019)
Figure Global Adenosquamous Carcinomas Revenue and Growth Rate (2017-2019)
Table Global MRNA Cancer Vaccines And Therapeutics Revenue and Revenue Share by Applications (2017-2019)
Figure Global Infectious Disease Revenue and Growth Rate (2017-2019)
Figure Global Cancer Revenue and Growth Rate (2017-2019)
Figure Global Other Revenue and Growth Rate (2017-2019)
Table Global MRNA Cancer Vaccines And Therapeutics Revenue by Regions (2017-2019)
Figure North America MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure North America MRNA Cancer Vaccines And Therapeutics Revenue and Growth Rate (2017-2019)
Figure North America MRNA Cancer Vaccines And Therapeutics by Countries (2017-2019)
Figure North America MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) by Countries (2017-2019)
Figure United States MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure United States MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Canada MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Mexico MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Europe MRNA Cancer Vaccines And Therapeutics Revenue and Growth Rate (2017-2019)
Figure Europe MRNA Cancer Vaccines And Therapeutics by Countries (2017-2019)
Figure Europe MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) by Countries (2017-2019)
Figure Germany MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Germany MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure France MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure UK MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Russia MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Italy MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Rest of Europe MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Asia-Pacific MRNA Cancer Vaccines And Therapeutics Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific MRNA Cancer Vaccines And Therapeutics by Countries (2017-2019)
Figure Asia-Pacific MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) by Countries (2017-2019)
Figure China MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure China MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Japan MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Korea MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure India MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Southeast Asia MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Rest of Asia-Pacific MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure South America MRNA Cancer Vaccines And Therapeutics Revenue and Growth Rate (2017-2019)
Figure South America MRNA Cancer Vaccines And Therapeutics by Countries (2017-2019)
Figure South America MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) by Countries (2017-2019)
Figure Brazil MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Brazil MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Argentina MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Columbia MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Rest of South America MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Middle East and Africa MRNA Cancer Vaccines And Therapeutics Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa MRNA Cancer Vaccines And Therapeutics by Countries (2017-2019)
Figure Middle East and Africa MRNA Cancer Vaccines And Therapeutics Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Saudi Arabia MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure United Arab Emirates MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Egypt MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Nigeria MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure South Africa MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Turkey MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa MRNA Cancer Vaccines And Therapeutics Growth Rate (2017-2019)
Figure Rest of Middle East and Africa MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2017-2019)
Table Moderna Therapeutics MRNA Cancer Vaccines And Therapeutics Financial Overview
Table CureVac MRNA Cancer Vaccines And Therapeutics Financial Overview
Table Translate Bio MRNA Cancer Vaccines And Therapeutics Financial Overview
Table BioNTech MRNA Cancer Vaccines And Therapeutics Financial Overview
Table Sangamo Therapeutics MRNA Cancer Vaccines And Therapeutics Financial Overview
Table Argos Therapeutics MRNA Cancer Vaccines And Therapeutics Financial Overview
Table In-Cell-Art MRNA Cancer Vaccines And Therapeutics Financial Overview
Table eTheRNA MRNA Cancer Vaccines And Therapeutics Financial Overview
Table Ethris MRNA Cancer Vaccines And Therapeutics Financial Overview
Table Tiba Biotechnology MRNA Cancer Vaccines And Therapeutics Financial Overview
Figure Global MRNA Cancer Vaccines And Therapeutics Revenue (Millions USD) and Growth Rate (2019-2027)
Table MRNA Cancer Vaccines And Therapeutics Market Forecast by Regions (2019-2027)
Figure North America MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure United States MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Canada MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Mexico MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Europe MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Germany MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure France MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure UK MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Russia MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Italy MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Rest of Europe MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Asia-Pacific MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure China MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Japan MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Korea MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure India MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Southeast Asia MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Rest of Asia-Pacific MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure South America MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Brazil MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Argentina MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Columbia MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Rest of South America MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Middle East and Africa MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Saudi Arabia MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure United Arab Emirates MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Egypt MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Nigeria MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure South Africa MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Turkey MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Rest of Middle East and Africa MRNA Cancer Vaccines And Therapeutics Market Forecast (2019-2027)
Figure Global MRNA Cancer Vaccines And Therapeutics Forecast by Type (2019-2027)
Figure Global MRNA Cancer Vaccines And Therapeutics Market Share Forecast by Type (2019-2027)
Figure Global MRNA Cancer Vaccines And Therapeutics Forecast by Type (2019-2027)
Figure Global MRNA Cancer Vaccines And Therapeutics Forecast by Applications (2019-2027)
Figure Global MRNA Cancer Vaccines And Therapeutics Market Share Forecast by Applications (2019-2027)
Figure Global MRNA Cancer Vaccines And Therapeutics Forecast by Applications (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|